Rounding Down Chemotherapeutic Agents to the Nearest Vial Size as a Cost Containment Measure
Journal Title: Cancer Studies & Molecular Medicine – Open Journal - Year 2017, Vol 3, Issue 1
Abstract
Background: High cancer treatment costs significantly affect health care expenditures. Drug waste reduction of costly drugs can reduce the treatment cost. Methods: A retrospective study conducted at King Abdulaziz Medical City (KAMC), Riyadh, Saudi Arabia. Adult patients above age of 14 years old who received chemotherapy between March 1st to March 31st, 2015 were included. Maximum dose rounding allowed was up to 10% for palliative intent and 5% for curative intent. Patients demographics, diagnosis, treatment intent (cure or palliation), ordered dose, rounded dose, vial size, number of vials that could be saved and expected cost saved per month were calculated and recorded. Results: A total of 305 patients received 973 doses of intravenous chemotherapy drugs during the study period. Orders of 352 doses could be rounded to the nearest vial size with a 10% dose deviation for palliative intent and 5% for curative intent. The projected savings for 1 month was calculated to be Saudi Riyals (SR) 14,720.95 for 5% rounding limit and SR 53,157.50 for 10% rounding which will account to an estimate of SR 814,514.40 of drug cost savings per year. Anti-cancer drugs with the most drug wastage due to non-rounding to the nearest vial size were trastuzumab, cyclophosphamide, etoposide, methotrexate, fluorouracil, paclitaxel, oxaliplatin, doxorubicin, bortezomib, and cytarabine consecutively. The highest costs savings when rounding the doses to the nearest vial size up to 5% for curative intent was associated with rituximab, followed by fludarabine and paclitaxel. Bevacizumab, cetuximab, and carfilzomib have resulted in the most cost savings when the rounding limit was set to 10% for palliative intent. Conclusion: Dose rounding of the ordered dose to an amount within 5% for curative intent and 10% for palliative intent to the nearest vial size has resulted in a valuable cost savings through reduction of drug wastage without any expected compromise in efficacy.
Authors and Affiliations
Nasser Mahdi Al-Qhtani
Keywords
Related Articles
- EP ID EP551980
- DOI 10.17140/CSMMOJ-3-116
- Views 121
- Downloads 0
How Target Therapy can Induce Cardiotoxicity: The Onco-Cardiologist Point of View
The life expectancy of an oncological patient has been increased significantly decades due to the evolution of cancer therapies. The aim of this paper is to review how these new target molecules, which have a direct impa...
Effects of Three Dimensional Microenvironment on Tumorigenicity of Fibrosarcoma in vitro
Tumor microenvironment plays an important role in cancer progression owing to interactions between the tumor and adjoining cells and, as in bone marrow, the unique architecture and chemical compounds that characterize it...
Elimination of Tumor Suppressor Proteins during Liver Carcinogenesis
Liver cancer is one of the most lethal cancers. Quiescent liver expresses up to 20 tumor suppressor proteins including Rb, p53, CCAAT-Enhancer-Binding Protein (C/EBP)α, Hepatocyte Nuclear Factor (HNF4)α and p16 and it is...
Dosimetric Characterization of an Abscopal Response in a Patient With Oligometastatic Melanoma Undergoing Concurrent Treatment With Pembrolizumab and Stereotactic Body Radiotherapy (SBRT)
Recently, preclinical and clinical evidence has shown that a synergy may exist between radiation and immune check-point therapies such as pembrolizumab. Radiation has been shown to activate the immune system, and in comb...
The Emerging Spectrum of Early Life Exposure-Related Inflammation and Epigenetic Therapy
Early life exposure to a variety of insults during sensitive windows of development can reprogram normal physiological responses and alter disease susceptibility later in life. During this process, inflammation triggered...